How reducing labor time can save on your cell therapy manufacturing costs
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
In the early clinical development stage of autologous cell therapy manufacture, labor costs often dominate the overall cost of goods (CoGs) sold. However, as manufacturing scales out, the cost of materials — including media and reagents, consumables, and viral vectors — increases as a percentage of the total CoGs. Ultimately, economies of scale can be achieved with autologous cell therapy processing. However, in order to widen access to these life-saving treatments, it’s crucial that manufacturers utilize solutions that can support reductions in labor costs.
In this webinar, our speakers will explain how you can reduce labor time for certain critical steps of autologous cell therapy manufacturing by using automated and closed systems. They’ll compare operator tasks in a standard process versus a process using Cytiva systems for specific steps, such as cell expansion, mononuclear cell enrichment, and cryopreservation.
- Identify the challenges faced in the industry today
- Understand the benefits of automated and closed systems
- Discover how Cytiva systems such as Xuri™ Cell Expansion System W25, Sepax™ C-Pro system, and VIA Freeze™ instruments can help to reduce labor time and save costs
SPEAKERS
You might also like
Improving cell therapy manufacturing with on-line monitoring of critical process parameters during cell expansion
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time
Key considerations for shortening your CAR-T manufacturing process
Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?
